（来源：千龙网） 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内，一批微生物"工人"已经开 工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产品。与2025年同期相比，在北京昌平区落户 的合成生物制造企业数量增长近七成，产业规模持续壮大，集聚效应日益凸显。 从实验室里的毫克级样品，到工业生产线上的吨级产品，园区内，微元合成生物技术（北京）有限公司 已成功实现甘露醇、阿洛酮糖、木糖醇等产品的商业化落地，聚焦人类营养、动物营养、日化原料、药 ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structure and transforming economic models [1]. Group 1: Current Status and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current state and trends of biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this sector [7]. Group 2: Policy Landscape - The white paper outlines major domestic and international policies affecting biomanufacturing from 2024 to 2025, providing insights into regulatory frameworks [7]. Group 3: Industry Map and Applications - It presents a comprehensive map of the Chinese biomanufacturing industry and identifies key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [7]. Group 4: Key Enterprises - The report selects ten leading enterprises in the Chinese biomanufacturing sector and details the strategic directions of 15 listed companies in synthetic biology [7][8]. Group 5: Investment and Challenges - The document discusses the investment landscape in synthetic biology from 2024 to mid-2025 and addresses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [7].

Policy Developments - The National Health Commission and 10 other departments jointly issued the "National Basic Drug Directory Management Measures," which revises six key areas, including legal policy basis, directory structure optimization, management mechanism improvement, emphasis on clinical value, dynamic adjustment mechanism, and monitoring and evaluation enhancement [1][2]. Drug and Device Approvals - Hengrui Medicine announced that its injection of Rukang Qutuzumab has been included in the list of breakthrough therapy varieties, marking the 10th indication for this drug, aimed at treating locally advanced or metastatic non-small cell lung cancer patients with HER2 mutations [3]. - Shanghai Pharmaceuticals received approval for the listing application of the raw material drug Tamsulosin Hydrochloride, which is used for treating benign prostatic hyperplasia, with an investment of approximately RMB 1.5 million in its development [4]. Financial Reports - WuXi Biologics expects a 46.3% year-on-year increase in net profit for the full year 2025, projecting revenues of approximately RMB 21.79 billion and an adjusted net profit of about RMB 6.59 billion [5]. - Eucare Pharmaceuticals reported a 48.21% decline in net profit for 2025, with revenues of RMB 334 million, reflecting a 7.73% increase [6]. Capital Markets - Watson Bio plans to invest RMB 450 million to establish a biological industry investment fund with a target size of RMB 1 billion, focusing on synthetic biology and related sectors [7]. - Hite Bio intends to acquire a 23.08% stake in Beijing Shadong for RMB 62.02 million, increasing its ownership to 98.84% [8]. - Duorui Pharmaceuticals announced a partial tender offer to acquire 24.30% of its shares at a price of RMB 32.07 per share [9]. Industry Events - China's first C909 "airplane hospital" successfully completed its first in-flight surgery in Laos, providing medical services to over 600 patients since its launch [10]. - Researchers revealed the key mechanism of the "weight loss miracle drug" Semaglutide, showing its significant cartilage protection effects independent of weight loss, providing new drug development targets for metabolic osteoarthritis [11]. Public Sentiment Alerts - Shuyou Shen announced that its major shareholder, Xiangtang Group, has cumulatively reduced its holdings by 4.78 million shares, accounting for 1% of the total share capital [12].

Group 1 - The National Health Commission and 11 other departments issued the "National Essential Drug Directory Management Measures," revising six key areas to enhance the essential drug system in China [1] - The revised measures include optimizing the directory structure, categorizing drugs into chemical drugs, biological products, and traditional Chinese medicine based on clinical pharmacology and functionality [1] - The management mechanism for the directory has been improved, emphasizing the clinical value of drugs and considering factors such as disease spectrum changes and drug supply assurance [1] Group 2 - Reborna Biotech and Madrigal Pharmaceuticals entered a global exclusive licensing agreement worth $4.4 billion to develop innovative siRNA therapies for metabolic dysfunction-related fatty liver disease (MASH) [2] - Reborna will receive a $60 million upfront payment and is eligible for additional payments upon achieving clinical development and regulatory milestones, along with royalties based on global net sales [2] - The agreement highlights the international value of domestic innovative drugs and the urgent demand for effective therapies in the MASH field, indicating significant market potential [2] Group 3 - Watson Bio announced plans to invest 450 million yuan to establish a biological industry investment fund, targeting a total fund size of 1 billion yuan [3] - The fund will primarily invest in the synthetic biology manufacturing sector, including areas such as synthetic biology, health, bio-agriculture, bio-energy, and bio-materials [3] - This initiative is expected to help Watson Bio capture industry benefits and lay the groundwork for future strategic mergers and acquisitions [3] Group 4 - Hengrui Medicine's subsidiary, Suzhou MSD Biopharmaceutical Co., has had its drug SHR-A1811 included in the list of breakthrough therapies by the National Medical Products Administration [4] - SHR-A1811 is intended for first-line treatment of locally advanced or metastatic non-small cell lung cancer patients with HER2 (ERBB2) activating mutations [4] - The inclusion of SHR-A1811 reflects Hengrui's research achievements in the ADC field, although it will face competition from several already approved similar products [4]

Core Viewpoint - The rapid growth of Weiyuan Synthesis, supported by comprehensive policies and funding from Changping District, highlights the district's commitment to becoming a hub for synthetic biology manufacturing and innovation [1][2]. Group 1: Company Development - Weiyuan Synthesis has expanded from 3 to over 400 employees, with a recent completion of nearly 300 million yuan in equity financing to accelerate the development of methanol-based bio-manufacturing products [1]. - The company has received 80 million yuan in investment from a municipal health fund, showcasing strong governmental support for its growth [1]. Group 2: Industry Ecosystem - Changping District has established 146 synthetic biology manufacturing companies and 16 common technology service platforms, with 56 new enterprises registered since 2024 and a total registered capital exceeding 300 million yuan [2]. - The district has been recognized as the first national-level characteristic industrial cluster in synthetic biology manufacturing, enhancing its brand visibility and demonstrating its role as a future industrial growth pole [1][2]. Group 3: Innovation and Technology - Significant original achievements have emerged from Changping, including the selection of a biological synthesis technology for 2-hydroxyhexanedioic acid as a major scientific achievement for the 2025 Zhongguancun Forum [3]. - Weiyuan Synthesis has received approval for the production of several products, including alulose and new yeast proteins, with multiple products accelerating through the approval process [3]. Group 4: Future Plans - Future City Group aims to enhance the innovation center's influence, attract quality teams, and promote technology transfer, with a goal of landing 10 landmark projects by 2026 [4]. - The establishment of a pilot base for synthetic biology manufacturing is planned to address challenges in technology transfer and further solidify the region's position in the industry [4].

Group 1: Market Outlook and Product Expansion - The coenzyme Q10 market has a broad outlook, expanding from the initial target group of individuals aged 65 and above and heart disease patients to include statin users, working professionals, and athletes. Demand in overseas markets remains stable, while domestic and emerging market demand is gradually being released [2]. - The company plans to expand its production capacity based on market demand assessments and its own advantages, ensuring a leading industry position and market share [2]. - The company’s 10,000-ton oil project will produce algae oil Omega-3, DHA, and ARA, utilizing microbial fermentation technology for efficient and scalable production, which is environmentally friendly and aligns with ESG principles [3]. Group 2: Raw Material and Product Development - The company maintains R&D investments in leading products like coenzyme Q10, continuously improving technology and processes to ensure cost leadership and product quality [3]. - New market opportunities are being explored to diversify product offerings, including algae oil Omega-3, yeast protein, and biological sweeteners [3]. - The yeast protein business is gaining attention for its high nutritional value and sustainability, with plans for further R&D and production [4]. Group 3: Nutritional Supplements and Market Strategy - The company’s nutritional supplement factory in the U.S. has overcome previous losses and is expanding production capacity and product lines, including soft capsules, to meet brand demands and increase profitability [5]. - Increased regulatory scrutiny on cross-border health products is expected to eliminate low-quality products, creating a fair market environment for compliant companies [6]. - The brand strategy for 2026 focuses on expanding market share and enhancing brand influence through increased marketing investment and optimized product channels [6][7].

Group 1 - The core point of the article is that Jinbo Bio has received approval from the China Securities Regulatory Commission (CSRC) for a targeted stock issuance, marking the first such approval for the Beijing Stock Exchange in 2024, which is expected to enhance the refinancing system for companies listed on the exchange [1][3] - Jinbo Bio plans to issue up to 7.1757 million shares, aiming to raise no more than 2 billion yuan, with the funds primarily directed towards the development of an AI research platform [1][2] - The strategic investor, Yangshengtang, is expected to help Jinbo Bio overcome development bottlenecks and stimulate the upstream and downstream enterprises in the industry chain [1] Group 2 - The funds raised will focus on the "Humanized Collagen FAST Database and Product Development Platform Project," which utilizes the company's self-developed "AI Collagen Brain System" technology to enhance efficiency in the development of humanized collagen [2] - The Beijing Stock Exchange has established a flexible and diverse refinancing mechanism since its inception, with the current focus on targeted convertible bonds and stock issuance, as evidenced by Jinbo Bio's successful registration [3] - The successful implementation of Jinbo Bio's stock issuance is expected to increase overall market attention on companies listed on the Beijing Stock Exchange, attracting various long-term funds and enhancing market liquidity [4]

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can drive industrial structure optimization and economic model transformation. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state and trends of biomanufacturing, analyzes the industry chain and key application directions, and provides insights into challenges and policy recommendations for the industry [1]. Group 1: Current State and Trends - The white paper outlines the development status and trends of biomanufacturing, including a comparative analysis of the biomanufacturing sectors in China and the United States [5]. - It discusses the key platform facilities in the global biomanufacturing industry, indicating the infrastructure necessary for growth [5]. - Future development trends in biomanufacturing are explored, suggesting potential directions for innovation and investment [5]. Group 2: Policy Landscape - The report details major policies affecting biomanufacturing both domestically and internationally, providing a comprehensive overview of regulatory environments [5]. - It categorizes foreign and domestic policies that impact the biomanufacturing industry, highlighting the importance of supportive regulations for growth [5]. Group 3: Industry Chain and Applications - An analysis of the biomanufacturing industry chain is presented, identifying key components and stakeholders involved in the sector [5]. - The report outlines several key application areas for biomanufacturing, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy, indicating the versatility of biomanufacturing technologies [5]. Group 4: Key Enterprises and Investment Landscape - The white paper identifies ten leading enterprises in China's biomanufacturing industry, showcasing significant players that are driving innovation and market growth [6]. - It also summarizes the strategic directions of 15 listed companies in synthetic biology, providing insights into their investment and development strategies [6]. - The investment and financing situation in the domestic synthetic biology sector for the period of 2024-2025 is discussed, indicating trends in capital flow and investment opportunities [6]. Group 5: Challenges and Recommendations - The report addresses the challenges faced by China's biomanufacturing industry, including technological, regulatory, and market-related issues that could hinder growth [6]. - Targeted policy recommendations are provided to address these challenges, aiming to foster a more conducive environment for the development of the biomanufacturing sector [6].

Company Overview - Dongxiao Biotechnology Co., Ltd. announced plans to publicly issue up to 28,207,567 shares to unspecified qualified investors and list on the Beijing Stock Exchange [1] - The public shareholders will hold no less than 25% of the total share capital after the issuance [1] - The company may utilize an overallotment option, allowing for an additional issuance of up to 15% of the public offering shares [1] Fundraising Purpose - The funds raised will be allocated to projects including functional sugar alcohol industrial upgrade, high-value amino acid intelligent construction, innovation R&D base, and working capital supplementation [1] Industry Insights - The global amino acid market is expected to grow at a compound annual growth rate (CAGR) of 4.7% from 2022 to 2027, reaching a production scale of 13.8 million tons by 2027 [2] - In 2023, China's share of global feed amino acid production (including lysine, methionine, threonine, and tryptophan) is projected to increase to 70.4% [2] - The Chinese plant-based cream market is estimated to reach approximately 9.008 billion yuan in 2023, with a year-on-year growth of about 9.99% [2] Financial Performance - The company reported a revenue of 7.84 billion yuan and a net profit of 578 million yuan for the year 2024, reflecting a year-on-year increase of 93.98% [2]

Core Insights - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can help optimize industrial structures and transform economic models [1]. Group 1: Current State and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current status and trends in biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this field [5]. Group 2: Policy Landscape - The white paper discusses major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. Group 3: Industry Map and Applications - It provides a comprehensive map of the Chinese biomanufacturing industry and analyzes the industry chain along with key application directions, including biomanufacturing in pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The report identifies ten leading enterprises in the Chinese biomanufacturing sector, detailing their contributions and roles within the industry [5][6]. Group 5: Company Strategies - It outlines the synthetic biology strategies of 15 listed companies, summarizing their development approaches and corresponding popular products [5][6]. Group 6: Investment and Challenges - The white paper reviews the investment and financing situation in domestic synthetic biology from 2024 to mid-2025 and discusses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [5][6].